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Polyamines are essential for life and are associated with cell cycle and 
development. Excess polyamine production occurs during tumor formation and is one 
possible target for chemopreventative and chemotherapeutic treatment. One enzyme, 
ornithine decarboxylase (ODC), plays a key role in polyamine biosynthesis. Among 
other regulators, the protein antizyme (Az) limits polyamine levels in the cell. It binds 
ODC and renders it unable to produce polyamines. The mechanism by which ODC and 
Az interact is unknown and is explored in this study.
It is known that ODC and Az have high affinity for one another, but the reason 
for the basal level of ODC activity that remains in excess Az in assays is unclear.
Varying the temperature and coenzyme concentrations in an assay revealed that these 
factors successfully changed the level of ODC activity at which the two proteins ceased 
to bind. The persistence of ODC activity in excess Az under several assay conditions 
showed that the remaining activity is not a result of the methods by which the assay is 










Modern cancer research explores a great diversity of biochemical pathways in 
the hopes of developing more effective chemotherapeutic and chemopreventative 
drugs. One promising area of research explores the roles of polyamines and the 
substances that regulate them as potentially effective mechanisms for treating cancer. 
Understanding their function, biosynthesis, transport, and catabolism in both healthy 
and cancerous ceils is key. It is also helpful to investigate the ways in which some 
regulators affect the development and inhibition of these compounds in vitro and in vivo 
in clinical trials. Further exploration in the less understood mechanisms of polyamine 
control could yield improved chemotherapy for patients and chemoprevention in high- 
risk groups.
Polyamines, including putrescine, spermidine and spermine, are essential for life 
and are associated with cell cycle and development. They are nutritive to normal cells 
and enable the increased growth of cancerous cells by promoting proliferation, 
differentiation and immortalization (Cohen 1998, Nishioka 1996). The polyamines are 
involved with ribosome function and protein synthesis, maintenance including apoptosis, 
and angiogenesis (Cohen 1998, Nishioki, et al 1996). In addition, spermidine is 
connected with the formation of hypusine, an amino acid that is necessary for protein 
synthesis in yeast and animal cells (Cohen 1998). It has also been discovered that 
reduced cellular polyamine levels decrease the rate of virus multiplication (Cohen 
1998). Clearly, polyamines serve key functions in the growth and maintenance of both 
normal and unhealthy cells.
Polyamines become available to cells by two means: they are either synthesized 
within the cells or they are consumed by an organism and then transported into the
cells. As shown in Figure 1, ornithine decarboxylase (ODC) converts ornithine to the 
W ' first polyamine putrescine in the rate-limiting step of polyamine synthesis. ODC is 
activated by GTP and is inhibited by a number of compounds including the protein 
antizyme (Az). ODC catalyzed biosynthesis of polyamines is limited by a feedback 
control mechanism. The presence of high levels of polyamines promotes translation of 
Az mRNA, creating a feedback loop in which polyamines that are synthesized inhibit 
further production of polyamines (Almrud 2000), as shown in Figure 1. ODC is a protein 
with an extremely short half-life, only about 20 minutes. Its short half-life and the 
diversity of conditions that strongly alter its activity indicate that its activity is highly 
controlled.
Figure 1: The Polyamine Biosynthetic Pathway
Az binds active ODC and renders it unable to produce polyamines. Az serves to 
inhibit ODC by binding it in its monomeric (unpaired) state, enabling conformational 
changes in ODC that expose its C terminus. The exposed C-terminus of the ODC 
allows it to be degraded by the 26S proteosome (Almrud 2000, Persson 1996). This
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idea is supported by the fact that ODC truncated at the C-terminus has a significantly 
W  longer half-life (Persson 1996). Given that high levels of polyamines are present in 
cancerous cells, Az provides one opportunity for chemopreventive and 
chemotherapeutic research.
While Az inhibits excessive cell growth and differentiation by inhibiting polyamine 
synthesis within the cell, it may also serve to limit polyamine levels by interfering with 
the polyamine transporter. Polyamines originate from the food consumed by an 
organism are transferred from the gastrointestinal tract to the cell. They can 
supplement the needs of cells that have become unable to synthesize sufficient 
amounts of polyamines “due to lack of substrates or to inhibition of ODC” (Persson 
1996). Transporter activity is stimulated by growth promoting agents, another group of 
compounds that are present in high levels in cancerous cells. Reducing the effects of 
growth promoting agents with Az in these cells could decrease the rate of cancerous 
growth.
The transporter is active during periods in which cells are deprived of polyamine 
synthesis. It is inactive when polyamines are present or in excess (Persson 1996). It is 
thought “that elevations in cellular polyamine levels stimulate the production of a labile 
protein that reversibly inactivates the polyamine transporter” (Mitchell 1994). Further 
evidence suggests that feedback response noted in polyamine transport may share a 
common intermediate with the response resulting in ODC instability (Mitchell 1994).
This implies that Az is one mechanism of transporter control. The mechanism by which 
Az inhibits polyamine transport remains unknown.
\mf/
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While a cell can limit polyamine production and transport into the cell, it must also 
W  retain the ability to catabolize polyamines. Polyamine catabolism can consist of
regression to a polyamine earlier in the metabolic pathway, acetylation for excretion, 
break-down into amino acids, or oxidation of putrescine for the formation of GABA, a 
neurotransmitter. Spermidine spermine acetyl transferase (SSAT), another well- 
regulated enzyme, acetylates its products and can convert spermine to spermidine and 
spermidine to putrescine. Polyamines “created” by SSAT can continue through 
metabolism or be excreted. The transacetylated product polyamines are far more easily 
excreted that their non-acetylated counterparts. SSAT is induced under conditions 
where a cell acquires high levels of polyamines due to toxins, hormones or the 
polyamines themselves (Persson 1996).
The polyamines may be catabolized into amino acids via a variety of pathways. 
^  One such example is the indirect relationship between putrescine, glutamate and
ornithine, shown in Figure 2. Interestingly, putrescine catabolism to amino acids occurs 
more frequently in aged cells than younger ones (Cohen 1998). This infers that there is 
some relationship between polyamine control mechanisms and senescence. One 
possible explanation is that older cells have increased amine oxidases (Cohen 1998).
As previously mentioned, putrescine can be converted into the inhibitory 
neurotransmitter GABA. The transformation can occur in both the brain and 
peripherally. The putrescine to GABA change is essentially the result of an oxidase, 
followed by an aldehyde dehydrogenase (Cohen 1998).
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Figure from Cohen (1998).
Neoplastic transformation, or the immortalization of cells, is linked with abnormal 
polyamine metabolism. Changes in polyamine synthesis, degradation, and excretion 
can be demonstrative of cancer (Cohen 1998). Evidence indicative of this association 
includes:
1. Increased excretion of polyamines by many cancer patients
2. Correlation of ODC content to the growth rates of certain cancers
3. Correlation of cellular ODC and polyamines to the growth rates of some tumor 
cells
4. Some effective cancer therapies decrease “abnormally high rates of 
polyamine synthesis” (Cohen 1998).
w
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Excess polyamine production occurs during tumor formation and slows with cancer 
remission. Because excessively high levels of polyamines have been associated with 
cancer, an opportunity has arisen for study into possible improvements in cancer 
diagnosis and chemotherapeutic or chemopreventative treatments involved with this 
pathway.
Increased ODC-catalyzed biosynthesis of polyamines can contribute to 
cancerous growth. The protooncogene c-myc enhances ODC transcription, resulting in 
increased levels of polyamine synthesis. This augmentation of polyamine synthesis is 
one characteristic of cancerous cells (Cohen 1998). ODC is associated with 
proliferation and hyperplasia (increased number of cells) (Cohen 1998) and its levels 
can correlate with malignancy. The strong correlation between ODC activity and cancer 
suggest that testing of ODC activity levels could be used to help diagnose cancers and 
that the polyamine biosynthetic pathway provides an excellent target for new 
chemotherapeutic and chemopreventative practices.
Regulation of polyamine levels must be highly controlled under normal conditions 
by the short-lived proteins ODC, SSAT and others. One mechanism by which excess 
polyamines contribute to cancerous growth is via constitutively active ODC. This ODC 
is no longer regulated, synthesizing polyamines without bound after the cell has been 
“transformed by carcinogens, viruses or oncogenes” (Almrud 2000). For this reason, 
substances that inhibit ODC activity could be productively explored in a laboratory 
setting. This inhibition could arise from “regulation of ode transcription, post- 
translational modification of ODC and negative feedback control” (Almrud 2000).
The close relationship between polyamine level control and cancer enable 
exploration into the development of clinically relevant improvements in the 
understanding of cancer. One such application is the advancement of clinical testing for 
cancer. Given the strong association of elevated polyamine levels in urine and red 
blood cells and cancer, it is possible that these levels could reveal the degree to which 
the cancer has advanced in a patient. (Cohen 1998). ODC activity could also be used 
to detect cancer. Increased activity was detected in “normal-appearing colonic mucosa 
. . .  in patients with familial polyposis” over that which was present in controls (Nishioki, 
et al 1996). This clinical trial indicates that the characteristic can be used as an 
effective biological marker for cancer. The efficacy of testing ODC activity as a marker 
in other organs is supported by similar results (Nishioki, et al 1996).
Inhibiting polyamine biosynthesis may also be used in chemotherapy of cancer.
A number of clinical studies targeting the pathway involved in polyamine biosynthesis 
have already begun, using polyamine analogs and other compounds. Eflornithine 
(DFMO) and methylglyoxyl-bis(guanylhydrazone) (MGBG) are two such potential 
chemotherapeutic agents. These agents are specifically targeted against ODC and a 
similar enzyme, AdoMetDC, respectively.
DFMO irreversibly inhibits ODC and leads to depletion of polyamines in the cells. 
Clinical studies involving DFMO have consisted of chemoprevention trials, anti­
trypanosomal therapy, and treatment of brain tumors and cervical dysplasia. (Nishioki 
154). While successfully reducing putrescine and spermidine levels, its effects on 
spermine levels are limited. “Limited clinical evaluation against solid tumors” in the 
1980s were unsuccessful “due to a lack of potency” (Kramer 1996). Later studies have
established its ability to limit polyamine synthesis in vitro and in vivo. Patients’ cancers 
did not enter remission, but some were stabilized and levels of circulating blast cells 
decreased in some of the patients (Nishioki, et al 1996). The side effects of DFMO 
treatment are nontoxic, relatively low and are reversible.
MGBG causes the inhibition of AdoMetDC, another polyamine biosynthetic 
enzyme. It serves to block spermidine synthesis, thereby reducing Az and 
subsequently increasing ODC activity. Clinical studies involving MGBG have dealt with 
non-Hodgkins lymphoma in AIDS patients. Clinical trials involving MGBG were initially 
unsuccessful because the compound remained in tissues for extended periods of time. 
Some of MGBG’s undesired effects include disruption of mitochondrial structure and 
function (Kramer 1996). However, it can be very effective against certain cancers, 
including non-Hodgkins lymphoma (Nishioki et al 1996). MGBG analogs that are more 
specific, and are therefore less likely to produce toxic side effects, have also been 
developed. One example of an MGBG analog with reduced potential side effects is 
CGP-48664. It binds ODC as a competitive inhibitor using an alternative transport 
mechanism and provides another opportunity for improved chemotherapeutic treatment.
The polyamine biosynthetic pathway has also been explored for the development 
of chemopreventative agents. Trials consisting of DFMO (the irreversible inhibitor of 
ODC) treatment to prevent cancer have been performed on animals that have been 
exposed to cancer-causing agents. The results were positive and clinical trials in 
humans have yielded similarly promising results with relatively low levels of side effects 
(Nishioki et al 1996). In a similar way, polyamine analogs may also prove to be effective 
in chemoprevention (Nishioki et al 1996).
Az provides another key opportunity for chemotherapeutic and 
W / chemopreventative treatment. Where DFMO only blocks ODC-catalyzed polyamine
biosynthesis, Az would be expected to inhibit both ODC activity and polyamine transport 
into the cells. This indicates that Az could more efficiently cause polyamine deficiency 
in affected cells, creating an environment in which cancerous growth would be inhibited. 
Further research into the role of Az in ODC inhibition and polyamine transport will 
provide the knowledge necessary to develop Az into a clinically effective 
chemotherapeutic and/or chemopreventative agent.
One aspect of Az inhibition of ODC that remains unclear is the mechanism by 
which Az binds ODC. While it is clear that Az and ODC have high affinity for one 
another, assays reveal a basal level of ODC activity that remains in excess Az. 
Understanding the mechanism by which some ODC activity is able to remain in excess 
V  Az could reveal new questions in the development of Az as a chemopreventative agent. 
Varying the conditions under which the assay is performed should elucidate the roles 
that different factors play in controlling the level of ODC activity at which ODC and Az 
cease to bind.
In this study, the most favorable conditions for ODC-Az interaction have been 
explored. A fixed amount of ODC was prepared to which increasing amounts of Az 
were added to excess. The amount of ODC activity was recorded and losses in ODC 
activity were attributed to interaction with Az, thereby revealing Az activity. This Az 
activity is compared across variables (temperature and presence or absence of 




To perform the assay, HTC (rat hepatoma) cells were first induced with 
W  methylglyoxyl-bis(guanylhydrazone) (MGBG) and dicyclohexylamine (DCHA). These
cells were used to provide the ODC activity. Other HTC cells were induced for Az using 
putrescine, making use of the feedback repression of ODC by polyamines. Graded 
amounts of Az were incubated with the ODC on ice for 15 minutes in buffer. After this 
reaction period the level of active ODC was determined by a UC release assay. 14C- 
labelled ornithine was added to the reaction vials. Filter paper that was treated with 
KOH was placed into the reaction vial stoppers. The KOH on the paper captured the 
14C-labelled product C02 during incubation After the stopper had been placed onto the 
reaction vial, the mixture was incubated and shaken at 37°C for one hour. Citric acid 
was injected into the vials to stop the reaction. The mixture was then incubated and 
shaken for 30 minutes. Following the assay, the filter paper was placed in scintillation 
fluid. The disintegrations of the 14C-label were expressed as the emission of light that 
was counted (in counts per minute) by a liquid scintillator. The radioactivity counted by 
the scintillator revealed the levels of ODC activity remaining and consequently the level 
of Az activity.The experimental conditions were varied in temperature (4° and 37°) and 
presence of absence of the coenzyme, pyridoxal phosphate (PLP). Temperature was 
expected to play a role in the level of Az activity because it affects the availability of 
ODC to interact. ODC remains homodimeric (paired ODC molecules) at 37°, but 
becomes monomeric (unpaired, open for interaction) at 4°. The addition of PLP, a 
coenzyme that promotes the formation of ODC dimers, should have decreased ODC 
inactivation by Az. A combination of these conditions should have revealed if the
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remaining ODC activity in excess Az was a result of the methods by which the assay 
W  was prepared.
Figure 3: Levels of ODC Inactivation
ODC-Az Interaction
Assay results revealed that the conditions under which the assay was prepared 
did play an important role in the level of ODC activity that remained in excess Az, as 
shown in Figure 3. The assays demonstrated that Az was able to inactivate more ODC 
at 4° than at 37°, as expected. Performing the assay at 4° allowed the ODC to remain in 
its monomeric state, which made it more readily available to promote polyamine 
synthesis. Under physiologic conditions (37°), the ODC should have been dimeric and 
would be expected to not be as susceptible to Az binding. The addition of PLP provided 
a similarly predictable result. Given that PLP is a coenzyme that encourages the 
formation of ODC dimers, it too decreased observed Az activity. While the variables
-11 -
successfully changed the activity level at which ODC-Az interactions ceased, they could
V  not entirely eliminate the enduring ODC activity.
The levels of ODC activity at which ODC and Az cease to bind varied from about 
65% of original activity (for the assay performed with PLP at 37°) to about 90% (for the 
assays performed at 4°). The fact that at least 10% of ODC activity was able to remain 
under all of the assay conditions explored indicates that the remaining activity is not a 
result of the methods by which the assay is prepared. The mechanism by which some 
ODC activity is allowed to remain in excess Az remains unclear. Though it is clear that 
Az is unable to completely inactivate ODC under various assay conditions, its function 
under normal physiologic conditions remains very important. Further inquiry will be 
needed to reveal more about how Az binds ODC and to discover what enables ODC 
activity to remain in excess Az.
^  Continuing research of the interactions between Az and ODC should elucidate
more about polyamine synthesis, inhibition and transport. Given the strong link 
between excessive polyamines and cell transformation and immortalization, repression 
of polyamine synthesis and transport into the cell could limit cancerous growth. Az 
serves as an effective inhibitor of both ODC-catalyzed polyamine synthesis and 
polyamine transport into cells. This combination is not shared by other compounds in 
the polyamine pathway, some of which have already proven successful in clinical trials. 
Using what is already known about these other regulators in the pathway as a 
background, learning more about Az inhibition of high levels of polyamines be helpful in 
establishing Az as a safe, effective chemotherapeutic and chemopreventative agent.
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